Much to "like" in draft guidance...
Consistent delivery of powerful innovations requires...
Increased innovation in the PCR industry,...
New optimism for pharma market prospects...
GEN Exclusives provide you with unique, in-depth, and critical coverage of key industry developments, market moving events, and scientific advances, as well as interviews with life science thought leaders. Also included are feature articles from GEN’s print edition.
Insight & Intelligence:
Jul 14, 2014
Find out who spent the most on developing the tools you use in the lab. [© Orlando Florin Rosu - Fotolia.com]
2013 R&D spending: $190.5 million
2012 R&D spending: $195.3 million
% Change: -2.5%
2013 R&D spending: $217.4 million (€ 159.8 million)
2012 R&D spending: $226.0 million (€ 166.1 million)4,5
% Change: -3.8%
2013 R&D spending: $210.952 million
2012 R&D spending: $209.204 million6
% Change: 0.8%
2013 R&D spending: $276.743 million
2012 R&D spending: $231.025 million
% Change: 19.8%
2013 R&D spending: $395.5 million7
2012 R&D spending: $376.4 million
% Change: 5.1%
2013 R&D spending: $476 million
2012 R&D spending: $418 million
% Change: 13.9%
2013 R&D spending: $494 million
2012 R&D spending: $472 million9,10
% Change: 4.7%
2013 R&D spending: $704 million11
2012 R&D spending: $668 million11
% Change: 5.4%
2013 R&D spending: Approx. $1 billion13
2012 R&D spending: Approx. $1 billion13
% Change: Unchanged
2013 R&D spending: $1.210 billion (CHF 1.081 billion)
2012 R&D spending: $1.145 billion (CHF 1.023 billion)5
% Change: 5.7%
Figures were disclosed by the companies in forms 10-K or 20-F, filed with the U.S. Securities and Exchange Commission (SEC); corporate annual reports; quarterly results press releases, and S-1 Securities Registration Statements also filed with the SEC. Where applicable, figures were converted to U.S. dollars from other currencies on July 7, 2014.</p>
<sup>1</sup> Figure reported to one decimal place in April 10, 2014 press release announcing selected 2013 results, with comparisons to 2012 results. This year as last, Eppendorf International disclosed R&D spending to tenths of a percent. See: <a href="http://corporate.eppendorf.com/uploads/media/20140410_PR_FYF2013_Eppendorf.pdf" target="_blank">http://corporate.eppendorf.com/uploads/media/20140410_PR_FYF2013_Eppendorf.pdf</a><br />
<sup>2</sup> Figure is the same as reported in company’s Form 10-K for 2012, but differs from the $54.115 million originally reported for 2012 in a company press release dated March 7, 2013. Sequenom last year restated previously filed financial statements and data for periods that included the first three quarters of 2012. The restatements included the reclassification to “selling and marketing expenses” a total $2.5 million spent during the nine-months ended September 30, 2012 by the Medical Affairs and Scientific Affairs departments, toward supporting the company’s selling efforts for its diagnostic testing services. Due to an accounting error, the cost was previously included within “research and development expenses”.<br />
<sup>3</sup> Figure has been restated from the $42.143 million (€30.972 million) reported a year earlier by Sartorius Stedim Biotech, and published by GEN in last year’s list. The change reflects the addition of $1.019 million (€749,000) in amortization and $73,000 (€54,000) in “other taxes” to R&D expenses, “in order to follow established international reporting practice and thus to provide financial data in the best comparable manner.” See the company’s annual report, titled Reference Document 2013, page 102: <a href="http://sw-gb.de/sartorius-stedim-biotech-sa_sr2/fileadmin/gb_512/gespdf/1203_ssb_doc_e_final_sec.pdf" target="_blank">http://sw-gb.de/sartorius-stedim-biotech-sa_sr2/fileadmin/gb_512/gespdf/1203_ssb_doc_e_final_sec.pdf</a><br />
<sup>4</sup> Merck Millipore is the division of Merck KGaA that supplies products and services for the life science industry. Key customer groups include research and analytical laboratories in the pharmaceutical/biotechnology industry or in academic institutions, and manufacturers of large and small molecule drugs.<br />
<sup>5</sup> 2012 dollar figure differs from that in last year’s GEN list of <a href="http://www.genengnews.com/insight-and-intelligence/top-22-r-amp-d-spenders-among-tool-and-technologies-companies/77899787/" target="_blank">Top 22 R&D Spenders Among Tools and Technology Companies</a>, published April 2, 2013, reflecting currency fluctuations since then.<br />
<sup>6</sup> Differs from the $214.040 million originally reported by Bio-Rad last year, and published by GEN in last year’s list. The reduction of $4.8 million reflects a reclassification of a refundable French R&D tax credit to the expense category “Provision for income taxes,” since the company is not required to have taxable income in order to earn the credit.<br />
<sup>7</sup> 2013 figure does not reflect Thermo Fisher’s acquisition of Life Technologies, which while announced April 13, 2013, was not completed until February 3, 2014. Life Technologies ceased reporting financial results after the third quarter of 2013, and thus is no longer included in this list.<br />
<sup>8</sup> Life Sciences & Diagnostics is the segment of Danaher Corp. that provides tools for biopharma research. Danaher’s life sciences business offer research and clinical tools used by scientists to study cells and cell components. Danaher’s diagnostics businesses offer analytical instruments, reagents, consumables, software, and services used by hospitals, physician’s offices, reference laboratories, and other critical care settings.<br />
<sup>9</sup> BD’s fiscal years encompass the 12 months ending September 30<br />
<sup>10</sup> Unlike 2012 fiscal year, BD reported FY 2013 R&D spending, and comparisons stretching back to 2009, to the nearest whole number rather than in thousandths, to three places to the right of the decimal, or $471.755 million, the figure published by GEN in last year’s list.<br />
<sup>11</sup> Agilent’s fiscal years encompass the 12 months ending October 31.<br />
<sup>12</sup> Includes GE’s drug discovery and biopharmaceutical manufacturing technologies businesses, as well as businesses focused on medical imaging and information technologies, medical diagnostics, and patient monitoring systems. In March, the company finalized its acquisition of Thermo Fisher Scientific's cell culture, gene modulation, and magnetic beads businesses for $1.1 billion.<br />
<sup>13</sup> Figures furnished to GEN by a company spokesman.<br />
<sup>14</sup> Includes Roche’s Professional Diagnostics, Diabetes Care, Molecular Diagnostics, and Tissue Diagnostics businesses. On April 23, 2013, Roche announced that the Applied Science business area’s portfolio of products would be integrated within the division’s other business areas. The polymerase chain reaction (PCR) technology, the nucleic acid purification (NAP) and biochemical reagents lines are now managed by Molecular Diagnostics. The Custom Biotech portfolio has moved to Professional Diagnostics. A dedicated unit has been established to focus solely on sequencing. </p>
To enjoy more articles like this from GEN, <a href="http://www.genengnews.com/subscriptions" target="_blank">click here to subscribe now</a>!</p>
Do you think genes strongly influence an individual’s political stand?
Be sure to add email@example.com
to your Address Book or Safe Senders List.
here for instructions.
If you have any questions about your subscription, click
here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
© 2014 Genetic Engineering & Biotechnology News All Rights Reserved